Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. H. Lundbeck A/S
  6. News
  7. Summary
    LUN   DK0010287234

H. LUNDBECK A/S

(LUN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

#1VoiceSummit: Partnering with the advocacy community to further brain health and neuroscience leadership

06/15/2021 | 09:18am EDT

'By discussing, listening to one another and partnering together, we are stronger. Brain diseases are complex: within the brain health community we need to align and agree on the evidence so we can debunk the myths and the stigma surrounding it. It requires persistence to systematically explain our case to policy makers and to get the funding needed to make the meaningful, positive and sustainable policy change required to support people with brain health conditions. Our aim is to get parity of care for brain health within the policy arena, so that people with brain health conditions are given the best shot at living their lives to the fullest. For that, we need a leadership that is collaborative, inclusive and which is ready to listen and co-create with the community. Alone we are invisible, united we are invincible,' says Maria Brandão, Senior Manager, Global Public Affairs at Lundbeck.

This year's speakers included leading experts in brain health, including Prof. Saxena from Harvard University and former WHO Director for Mental Health, Brad Herbert from Healthy Brains Global Initiative, Joke Jaarsma from the OneNeurology Initiative and Simone Boselli from The European Association of Rare Diseases (EURORDIS). These experts talked about the importance of collaboration and of strategy in order to position brain health.

On day two of the #1VoiceSummit the focus was on fundraising. Speakers included representatives from the Lundbeck Foundation, Alzheimer's Disease International, and Changing Minds Globally.

Additionally, Lundbeck's CEO, Deborah Dunsire, joined the live Q&A in which she shared the importance of partnering with people with lived experience to make the most meaningful treatments and societal change.

The event a great opportunity to see the challenges and opportunities from the lens of patient groups in different countries. Few organizations are organized at the international level and the event gives groups an opportunity to learn from each other and share experience through Q&A sessions and collaborative workshops. Some advocacy groups have been around longer than others and offer valuable lessons learned, while other, newer groups have gained great insight by having people with valuable fund raising and advocacy experience show them the way.

So often I feel that companies and those outside of the mental health arena don't deeply listen to how we can create sustainable change going forward but I felt that Lundbeck was really listening. It was great to be a part of the summit. Anna Sackett Rountree, Director of Communications, Clubhouse International

'So often I feel that companies and those outside of the mental health arena don't deeply listen to how we can create sustainable change going forward but I felt that Lundbeck was really listening. It was great to be a part of the summit,' says Anna Sackett Rountree, Director of Communications, Clubhouse International, which is a group dedicated to end social and economic isolation for people with mental illness by growing the number and quality of Clubhouse rehabilitation programs worldwide.

If you are a representative of an advocacy group who is interested in attending the #1VoiceSummit, please contact your local Lundbeck office or contact publicaffairs@lundbeck.com.

Disclaimer

H. Lundbeck A/S published this content on 15 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 June 2021 13:17:00 UTC.


ę Publicnow 2021
All news about H. LUNDBECK A/S
07/22H LUNDBECK A/S : What do you mean brain health?
PU
07/01Denovo Biopharma LLC Announces In-Licenses Late-Stage Alzheimer's Disease Ass..
CI
06/15#1VOICESUMMIT : Partnering with the advocacy community to further brain health a..
PU
06/11H LUNDBECK A/S : Lundbeck CEO, Deborah Dunsire, warns that we could be on the br..
PU
05/31H LUNDBECK A/S : Interpretation Of The Term "export" In The Indian Patent Contex..
AQ
05/26H LUNDBECK A/S : Transactions with shares and linked securities in H. Lundbeck A..
AQ
05/24H LUNDBECK A/S : The Hunt for a New Weapon Against Schizophrenia
PU
05/20Verantos and Lundbeck Announce Partnership for Migraine Care Implementing Adv..
CI
05/11H LUNDBECK A/S : Lundbeck delivers a solid EBIT of DKK 882 million and Vyepti is..
AQ
05/11H. Lundbeck A/S Provides Revenue Guidance for the Full Year of Fiscal 2021
CI
More news
Financials
Sales 2021 16 626 M 2 642 M 2 642 M
Net income 2021 1 484 M 236 M 236 M
Net Debt 2021 2 283 M 363 M 363 M
P/E ratio 2021 27,4x
Yield 2021 1,69%
Capitalization 37 415 M 5 954 M 5 947 M
EV / Sales 2021 2,39x
EV / Sales 2022 2,11x
Nbr of Employees 5 551
Free-Float 30,7%
Chart H. LUNDBECK A/S
Duration : Period :
H. Lundbeck A/S Technical Analysis Chart | LUN | DK0010287234 | MarketScreener
Technical analysis trends H. LUNDBECK A/S
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 188,30 DKK
Average target price 240,93 DKK
Spread / Average Target 28,0%
EPS Revisions
Managers and Directors
Deborah L. Dunsire President & Chief Executive Officer
Anders G÷tzsche Chief Financial Officer & Executive Vice President
Lars S°ren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
H. LUNDBECK A/S-9.82%5 954
JOHNSON & JOHNSON9.71%454 682
ROCHE HOLDING AG11.50%329 752
PFIZER, INC.14.37%235 663
NOVARTIS AG-0.44%221 987
ELI LILLY AND COMPANY44.27%221 420